Skip to main content
. 2017 Oct 24;8(1):2045893217741429. doi: 10.1177/2045893217741429

Fig. 4.

Fig. 4.

Dual ETA/ETB and selective ETB receptor antagonism decreases proliferation in isolated PASMCs of patients with PAH. Treatments with dual ETA/ETB receptor antagonist (macitentan) or selective ETB receptor antagonist (BQ788) at maximal dose (10–6 M) reduced the proliferation of PAH–PASMCs when compared to vehicle-treated cells. KI67 immunofluorescence (in red) and DAPI (in blue) was performed to quantify proliferation. Note that we observed no statistical changed in proliferation after selective ETA receptor antagonist (BQ123) treatment in PAH–PASMCs. While apoptosis rate (AnnexinV in green) was decreased in PAH–PASMCs compared to control PASMCs, no significant changes in apoptosis rate were observed after treatment with dual or selective ET-1 receptor antagonists. Two independent sets of experiments were performed in each cell lines. In each experiment, a minimum of 150 cells were evaluated (n = 3 cell lines/treatment, passage 4–6). Scale bar: 50 µm. *P < 0.05; **P < 0.01; ***P < 0.001.